Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA-4948, Pembrolizumab, and SRS in Melanoma Brain Metastases
NCT05669352Phase 2Suspended
- Sponsor
- Mayo Clinic
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of emavusertib in melanoma, sponsored by Mayo Clinic. Started Nov 2026; status: suspended.
02
Drugs
emavusertib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05669352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669352.